Rivastigmine
Rank #333 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$31.4M
Total Cost
118,567
Total Claims
$31.4M
Total Cost
4,295
Prescribers
$265
Cost per Claim
11,704
Beneficiaries
158,895
30-Day Fills
$7,321
Avg Cost/Provider
28
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$31.4M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $31.4M total
Top Prescribers of Rivastigmine
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Vlad Nusinovich | Internal Medicine | West Hollywood, CA | 510 | $156K |
| 2 | Rene Sanchez-Borrero | Neurology | Bayamon, PR | 675 | $135K |
| 3 | Teresa Castro Ponce | Neurology | Guaynabo, PR | 616 | $134K |
| 4 | James Rider | Family Practice | Winchester, KS | 581 | $129K |
| 5 | Tziporah Kay | Physician Assistant | Brooklyn, NY | 315 | $127K |
| 6 | Mary Mcphail-Ciufo | Neurology | Grand Rapids, MI | 427 | $120K |
| 7 | Maria Wiscovitch | Neurology | Fajardo, PR | 427 | $120K |
| 8 | Scott Avery | Family Practice | Junction City, KS | 463 | $98K |
| 9 | Michael Amoashiy | Neurology | Brooklyn, NY | 114 | $98K |
| 10 | Ramsey Falconer | Neurology | Alexandria, VA | 215 | $95K |
| 11 | Hector Santos | Neurology | Carolina, PR | 395 | $94K |
| 12 | Fernando Gonzales-Portillo | Internal Medicine | Orlando, FL | 488 | $91K |
| 13 | Michael Amoashiy | Neurology | Brooklyn, NY | 432 | $87K |
| 14 | Carlo Bayrakdarian | Psychiatry | White Plains, NY | 385 | $86K |
| 15 | Jyh-Haur Lu | Neurology | Flushing, NY | 335 | $81K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
| 332 | Voxelotor (Oxbryta) | $31.5M | 2,707 |
| 333 | Rivastigmine (Rivastigmine) | $31.4M | 118,567 |
| 334 | Zolpidem Tartrate (Zolpidem Tartrate) | $31.3M | 3,144,599 |
| 335 | Lorazepam (Lorazepam) | $31.3M | 3,237,827 |
| 336 | Diphth,pertuss(Acell),tet Vac (Boostrix Tdap) | $31.2M | 466,555 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology